Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Active, not recruiting · NCT04699838 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Active, not recruiting | Phase 2 | 2026-09-03 | NCT04699838 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Muhammad Furqan | 1 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 38 |
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |
| University Of Illinois Medical Center | Chicago | United States | 3 |
| University of Iowa Hospitals and Clinics | Iowa City | United States | 99 |
| University of Maryland | Baltimore | United States | 86 |